A Safety and Efficacy Study of LYS-GM101 Gene Therapy in Patients With GM1 Gangliosidosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-05-11

Study Completion Date

2023-05-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

LYS-GM101 is a gene therapy for GM1 gangliosidosis intended to deliver a functional copy of the GLB1 gene to the central nervous system. This study will assess, in a 2-stage adaptive-design, the safety and efficacy of treatment in subjects with infantile GM1 gangliosidosis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis

NCT04713475

GM1 Gangliosidosis GM1 Gangliosidosis, Type I GM1 Gangliosidosis, Type 2 +1 more

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease

NCT02416661

Lysosomal Storage Diseases Gaucher Disease Sphingolipidoses

COMPLETED

Safety and Efficacy of GS-100 Gene Therapy in Patients With NGLY1 Deficiency

NCT06199531

NGLY1 Deficiency

RECRUITING PHASE1/PHASE2

A Gene Therapy Study in Patients With Gaucher Disease Type 1

NCT05324943

Gaucher Disease, Type 1

COMPLETED PHASE1

First-in-Human Study of TSHA-101 Gene Therapy for Treatment of Infantile Onset GM2 Gangliosidosis

NCT04798235

Infantile GM2 Gangliosidosis (Disorder)

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

GM1 gangliosidosis is a fatal autosomal recessive disease caused by mutations in the GLB1 gene leading to accumulation of GM1 ganglioside in neurons and progressive neurodegeneration. There are three pediatric subtypes: early infantile, late infantile and juvenile. This is an interventional, multicenter, single-arm, 2-stage adaptive design study of LYS-GM101 for which the first stage (Stage 1) is for safety evaluation (FIH) and the second stage (Stage 2) will establish efficacy as compared to the natural history of the disease. The participants with infantile GM1 gangliosidosis will receive a single dose of LYS-GM101 by intracisternal injection. After a two-year evaluation period (main part of the study), each participant will be followed for an additional three-year long-term follow-up period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

GM1 Gangliosidosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

8x10^12 vg/Kg LYS-GM101

Subjects will receive a single infusion: 8x10\^12 vg/Kg LYS-GM101

Group Type EXPERIMENTAL

LYS-GM101

Intervention Type GENETIC

LYS-GM101 is an adeno-associated viral vector serotype rh.10 (AAVrh.10) carrying the human β-galactosidase gene, formulated as a suspension for injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LYS-GM101

LYS-GM101 is an adeno-associated viral vector serotype rh.10 (AAVrh.10) carrying the human β-galactosidase gene, formulated as a suspension for injection

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Documented GM1 gangliosidosis diagnosis based on genotyping confirming the β-gal gene mutations and/or documented deficiency of β-gal enzyme by laboratory testing
* Children with early infantile GM1 gangliosidosis less than 12 months of age with ability to swallow
* Children with late infantile GM1 gangliosidosis less than 3 years of age with ability to sit

Exclusion Criteria

* Uncontrolled seizure disorder. Patients who are stable on anti-convulsive medications may be included
* More than 40% brain atrophy as measured by MRI total brain volume at screening
* Current participation in a clinical trial of another investigational medicinal product
* Past participation in a gene therapy trial
* History of hematopoietic stem cell transplantation
* Any condition that would contraindicate treatment with immunosuppressant therapy
* Presence of concomitant medical condition or anatomical abnormality precluding lumbar puncture or intracisternal injection
* Presence of any permanent items (e.g., metal braces) precluding undergoing MRI
* History of non-GM1 gangliosidosis medical condition that would confound scientific rigor or interpretation of results
* Rare and unrelated serious comorbidities, e.g., Down syndrome, intraventricular hemorrhage in the new-born period, extreme low birth weight (\<1500 grams) or known bleeding disorders
* Any vaccination 1 month prior to the planned immunosuppressant treatment
* Serology consistent with HIV exposure or consistent with active hepatitis B or C infection
* Grade 2 or higher lab abnormalities for Liver function tests (LFT), bilirubin, creatinine, hemoglobin, white blood cell (WBC) count, platelet count, prothrombin time (PT), and partial thromboplastin time (PTT), according to CTCAE v5.0

Maximum Eligible Age

3 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No